Production (Stage)
InnoCan Pharma Corporation
INNPF
$0.114
-$0.007-5.79%
OTC PK
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.19% | 10.38% | 111.22% | 176.96% | 333.85% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.19% | 10.38% | 111.22% | 176.96% | 333.85% |
| Cost of Revenue | -11.21% | 64.24% | 101.67% | 38.92% | 303.68% |
| Gross Profit | 18.56% | 2.80% | 112.31% | 201.13% | 338.03% |
| SG&A Expenses | -5.05% | 6.97% | 58.82% | 148.36% | 234.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.43% | 9.21% | 56.40% | 128.06% | 182.38% |
| Operating Income | 140.35% | -2.80% | 129.19% | 222.02% | 4.27% |
| Income Before Tax | 102.70% | 100.52% | 138.42% | 462.12% | 0.65% |
| Income Tax Expenses | 11.97% | -76.17% | -- | -- | -- |
| Earnings from Continuing Operations | 84.25% | 93.97% | 115.54% | 341.41% | -18.40% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -12.78% | 24.14% | -187.00% | -399.19% | -645.24% |
| Net Income | 67.06% | 87.09% | 85.69% | 164.81% | -39.13% |
| EBIT | 140.35% | -2.80% | 129.19% | 222.02% | 4.27% |
| EBITDA | 141.51% | -3.05% | 130.16% | 226.93% | 4.53% |
| EPS Basic | 69.23% | 87.88% | 87.18% | 157.14% | -27.45% |
| Normalized Basic EPS | 72.50% | 88.24% | 90.38% | 166.67% | -25.00% |
| EPS Diluted | 69.23% | 87.88% | 87.18% | 147.62% | -27.45% |
| Normalized Diluted EPS | 72.50% | 88.24% | 90.38% | 166.67% | -25.00% |
| Average Basic Shares Outstanding | 7.60% | 7.47% | 9.04% | 11.43% | 7.61% |
| Average Diluted Shares Outstanding | 7.60% | 7.47% | 9.04% | 11.43% | 7.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |